重组融合蛋白Ph-PA对绿脓杆菌体内体外抗菌活性的初步研究

目的制备和纯化抗绿脓杆菌工程多肽Ph-PA，并检测其对绿脓杆菌的体内外抗菌活性。方法经离子交换柱纯化收集Ph-PA后，通过体外抗菌试验和体内感染保护试验并与现有抗生素对比，检测其抗菌活性。结果体内外抗菌实验结果显示Ph-PA对绿脓杆菌有较强的抗菌作用，且表现出相对的靶向特异性，对绿脓杆菌ATCC 27853的最小抑菌浓度（MIC）为4μg／mL。按照相同相对分子质量进行标化后比较，Ph-PA的抗菌活性至少是哌拉西林的2200倍，头孢他啶的220倍。结论Ph-PA在体外及体内对绿脓杆菌都表现出较强的抗菌活性，为治疗绿脓杆菌感染提供了新的思路，具有临床应用潜力。

Preliminary Study on Antibacterial Activity of Recombinant Fusion Protein Pheromonicin-PA to Pseudomonas aeruginosa in vitro/in vivo

Objective To prepare the engineering peptide Pheromonicin-P.aeruginosa (Ph-PA) and evaluate the antibactericidal activity of prepared Ph-PA against P.aeruginosa via in vitro/in vivo bactericidal assays. Methods Ph-PA was purified by CM sepharose ion-exchange column. In vitro/in vivo bactericidal assays were performed to identify the antibactericidal activity of Ph-PA against P.aeruginosa. Results In vitro and in vivo data showed that antibactericidal effects of Ph-PA, on molar basis, were approximately over 2200 times greater than that of piperacillin, and 220 times greater than that of ceftazidime against P.aeruginosa. Conclusion The Ph-PA may have potentially applied value as a novel kind of peptide antibiotics against P.aeruginosa infection.